APA (7th ed.) Citation

Boettcher, M., Heinig, R., Schmeck, C., Kohlsdorfer, C., Ludwig, M., Schaefer, A., . . . Weber, O. (2012). Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60–5521, a potent inhibitor of cholesteryl ester transfer protein. British journal of clinical pharmacology, 73(2), 210-218. https://doi.org/10.1111/j.1365-2125.2011.04083.x

Chicago Style (17th ed.) Citation

Boettcher, Michael‐Friedrich, Roland Heinig, Carsten Schmeck, Christian Kohlsdorfer, Matthias Ludwig, Anja Schaefer, Sabine Gelfert‐Peukert, Georg Wensing, and Olaf Weber. "Single Dose Pharmacokinetics, Pharmacodynamics, Tolerability and Safety of BAY 60–5521, a Potent Inhibitor of Cholesteryl Ester Transfer Protein." British Journal of Clinical Pharmacology 73, no. 2 (2012): 210-218. https://doi.org/10.1111/j.1365-2125.2011.04083.x.

MLA (9th ed.) Citation

Boettcher, Michael‐Friedrich, et al. "Single Dose Pharmacokinetics, Pharmacodynamics, Tolerability and Safety of BAY 60–5521, a Potent Inhibitor of Cholesteryl Ester Transfer Protein." British Journal of Clinical Pharmacology, vol. 73, no. 2, 2012, pp. 210-218, https://doi.org/10.1111/j.1365-2125.2011.04083.x.